A FTIH Study With GSK3008348 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis

Trial Profile

A FTIH Study With GSK3008348 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs GSK 3008348 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; First in man
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Mar 2018 According to results published in the European Journal of Clinical Pharmacology, objectives of the study were achieved after the first two dosing periods in cohort 3; therefore, the study was terminated and the final two dosing periods in cohort 3 were not required.
    • 12 Mar 2018 Status changed from recruiting to discontinued.
    • 12 Mar 2018 Results (n=29) assessing safety, tolerability and pharmacokinetic (PK) profile of single doses of GSK3008348 in healthy participants, were published in the European Journal of Clinical Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top